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ABSTRACT
Background In hereditary forms of cancer due to
mutations of genes such as BRCA1 and BRCA2,
methods have been proposed to predict the presence of
a mutation in a family.
Methods Relying on carriage probability computation
is the most predictive, but scores are a good proxy and
avoid using computer software. An empirical method,
the Manchester scoring system, has been elaborated for
BRCA1 and BRCA2 mutation identiﬁcation. We propose
a general scoring system based on a transformation of
the carriage probability. Up to an approximation, the
transformed carriage probability becomes an additive
score. We applied this new scoring system to the
diagnosis of BRCA1-associated and BRCA2-associated
breast–ovarian cancer predisposition. Using simulations,
its performance was evaluated and compared with that
of the Manchester scoring system and of the exact
probability. Finally, the score system was used on a
sample of 4563 families screened for BRCA1 and
BRCA2 mutations.
Results The performance of the new scoring system
was superior to the Manchester scoring system, but the
probability computation remained the most predictive.
The better performance of the new scoring system was
attributed to accounting for unaffected family members
and for the degree of kinship of relatives with the
proband.
Conclusions The new scoring system has a theoretical
basis and may be applied to any cancer family syndrome
and, more generally, to any disease with monogenic
subentities, in which the causal gene mutations have
been identiﬁed. It will be easily modiﬁed when
additional predictive factors are found.
INTRODUCTION
Hereditary forms of cancer have been described for
many years, and some of them are due to known
rare mutations of genes, such as BRCA1 and
BRCA2 for breast–ovarian cancer and the mismatch
repair genes for colorectal and gynaecological
cancers. Individuals who have inherited a deleteri-
ous mutation have a highly increased risk of devel-
oping cancer.1 2 It is essential to identify the
families in which such mutations segregate to
provide efﬁcient counselling to individuals at risk
and to ensure appropriate medical management of
mutation carrier individuals.3–6
The low carriage frequency, the high incidence
of these cancers and the high cost of testing render
the exhaustive screening of mutations in the
population impractical. Hence, several models that
use individual (age at onset, type of cancer, etc.)
and family information have been proposed to
more efﬁciently target the high-risk population,
and criteria for recommendation of genetic testing
to affected individuals have been deﬁned.7
For BRCA1 and BRCA2 mutations, some of these
criteria are based on carriage probability computed
according to characteristics of individuals in a
family through a variety of algorithms.8–10 Another
approach, the Manchester scoring system,11 12 allo-
cates a score to each affected individual in a family
and computes the sum of the scores in the maternal
and paternal lineage; if one of these two sums
exceeds a given threshold, usually corresponding to
a 10–20% mutation probability, a genetic test is
recommended. Finally, some recommendations for
genetic testing are based on a list of speciﬁc family
conﬁgurations regarding affection status and age at
onset of family members. They are the most com-
monly used in France.13 14 Methods that compute
the carriage probabilities are the most predictive
ones, but they are not used by the majority of
geneticists (genetic counsellors), particularly in
France, because they require using a computer soft-
ware and data entering for all family members,
which they consider time consuming.14 Scoring
systems avoid data entry and are a good proxy to
probability computations. Moreover, they may
easily be modiﬁed to include potential new relevant
predictive factors.15
The Manchester scoring system is empirical as
the scores have been determined to ﬁt the observa-
tions made in a group of selected families tested for
BRCA1 and BRCA2 mutations. Moreover, it does
not take into account information on unaffected
family members, the presence of which is expected
to decrease the probability of mutation, and gives
the same weight to all affected family members
whatever their degree of kinship.
In Bonaïti et al,14 we advocated to the French
physicians the use of a new scoring system for the
diagnosis of BRCA1-associated or BRCA2-associated
(referred as BRCA1/2) breast–ovarian cancer predis-
position. In this scoring system, the scores can be
calculated by the physician in a similar way to the
Manchester scores. The presentation of the theoret-
ical foundations on which it relies was deferred to a
subsequent publication. The aim of the present
study is to give a detailed description of this general
scoring system, which is based on an approximation
of the probability of an affected individual to be a
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carrier conditional to his/her family history, and to compare the
performance of this new scoring system with the Manchester
scoring system and to the exact probability. We also used the
score system on a sample of 4563 families from the Institut Curie
in Paris tested for BRCA1/2 mutations and present the results
here.
METHODS
Disease model
We consider a predisposing cancer syndrome, due to a dominant
mutated gene, involved in various tumour localisations j and
various tumour characteristics c, such as the ‘triple-negative’
(TN) phenotype in breast cancer16 or the MSI phenotype in
colorectal cancer.17 Let Fðt; g; jÞ be the cumulative risk of devel-
oping a tumour at localisation j by age t (in years) for carrier
status g (g=1 for a carrier and g=0 for a non-carrier). For
affected individuals, the probability of tumour characteristic c is
designed by rðc; g; jÞ:An observation is deﬁned by (s,c,t), where s
equals 1 or 0 according to the affected status of the individual,
and t is age at onset for affected persons and censored age for
unaffected ones. The probability Fðs; c; t; g; jÞ of this observa-
tion depends on carrier status g and on localisation j:
Fðs; c; t; g; jÞ ¼ðFðtþ 1; g; jÞ  Fðt; g; jÞÞrðc; g; jÞ if s ¼ 1
¼1 Fðtþ 1; g; jÞ if s ¼ 0
Sex is directly taken into account by considering different values
of j for men and women for a same localisation.
Elaboration of the scoring system
The scoring system is proposed as a surrogate for the probability
of a proband, in a given family, to be a mutation carrier. This
scoring system is derived from a conditional probability P, which
is evaluated by taking into account the proband’s personal and
family history of the disease and may be written according to
Bayes’ theorem as
P ¼ Pr ðg1 ¼ 1jHÞ ¼
p
pþ ð1 pÞ
Pr ðHjg1 ¼ 0Þ
Pr ðHjg1 ¼ 1Þ
;
where H represents the personal and family history, that is, all
the observations ðsij; cij; tijÞ for each localisation j and each
family member i, g1 is the carrier status of the proband and p is
the carrier frequency in the population.
A ﬁrst approximation consists in considering that two family
members have no other common relative than the proband and
that Pr ðgi ¼ 1 jg1 ¼ 1Þ ¼ 0:5
di , where di is the degree of kinship
of family member i with the proband (0 for the proband, 1 for
ﬁrst-degree relatives, 2 for second-degree relatives, etc.). We
obtain
Pr ðHjg1 ¼ 0Þ ≃
Y
i
Y
j
Fðsij; cij; tij; 0; jÞ
Pr ðHjg1 ¼ 1Þ ≃
Y
i
0:5di
Y
j
Fðsij; cij; tij;1; jÞ þ ð1 0:5
diÞ
Y
j
Fðsij; cij; tij;0; jÞ
 !
Hence, we can write
Pr ðHjg1 ¼ 1Þ
Pr ðHjg1 ¼ 0Þ
≃
Y
i
 
1þ 0:5di
Y
j
Fðsij; cij; tij;1; jÞ
Fðsij; cij; tij;0; jÞ
 1
!
;
and
S:¼log
PrðHjg1¼1Þ
PrðHjg1¼0Þ
 
≃
X
i
log
 
1þ0:5di
Y
j
Fðsij;cij;tij;1;jÞ
Fðsij;cij;tij;0;jÞ
1
!
;
P≃
p
pþð1pÞexpðSÞ
:
The sum over all family members in S, which we call the score
of the family, is then approximated as
S≃
X
i
"
Gi
X
j
Iijlog

1þ0:5diðLðsij;cij;tij;jÞ1Þ

þð1GiÞlog

1þ0:5diðLðsij;cij;tij;jÞ1Þ
#
where Gi and Iij are two dummy variables: Gi¼1 if the individual
is affected by at least one localisation and 0 if not, Iij¼1 if the
individual is affected by localisation j and 0 if unaffected, and
Lðsij;cij;tij;jÞ¼
Fðsij;cij;tij;1;jÞ
Fðsij;cij;tij;0;jÞ
:
If s=1, this ratio is the relative risk for a carrier of being affected
by a tumour of localisation j.
Using this approximation (S), one neglects the fact that a
person affected with a given cancer is unaffected by the other
cancer localisations and considers that cancers for a given indi-
vidual occur independently.
The computation of the global score S for a family is then
obtained by summing the elementary scores:
▸ sðt; j; cÞ ¼ logð1þ 0:5diðLð1; c; t; jÞ  1ÞÞfor each occurrence
of a cancer in the family
▸ snðt; xÞ ¼ logð1þ 0:5dið
Q
j[Jx
Lð0; 0; t; jÞ  1ÞÞ for each una-
ffected individual of sex x, where Jx represents the localisa-
tions related to sex x
If there are mutations on several genes, we propose to use for
Lðsij; cij; tij; jÞ the average value in carriers of the different gene
mutations weighted by their frequency in the population.
Finally, we note the two reciprocal relationships between S
and P:
P ≃
p
pþ ð1 pÞ expðSÞ
and
S ≃  log
ð1 PÞ=P
ð1 pÞ=p
 
:
Application to the diagnosis of BRCA1/2-associated
breast–ovarian cancer predisposition
Carriers of BRCA1/2 gene mutations have an increased risk not
only of breast and ovarian cancer but also of pancreas and pros-
tate cancer.18 19 In addition, it has been shown that the type of
breast pathology, particularly TN tumours, that is, negative for
oestrogen receptor (ER), progesterone receptor (PR) and HER2
expression, inﬂuences the probability of detecting a BRCA1
mutation, but not a BRCA2 mutation.16
For assessing the ratios of probabilities Λ(s,c,t;j) necessary to
the determination of the scores, penetrance values were taken
from the meta-analysis of Chen and Parmigiani1 for female
breast cancer and ovarian cancer, from Tai et al20 for male
breast cancer and from van Asperen et al19 and Risch et al18 for
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pancreas and prostate cancers. In cases where the risks at greater
ages were not provided by these sources, we inferred the
missing data from available data by ﬁtting a mixture model with
a subgroup of non-susceptible carrier individuals and a sub-
group of susceptible carriers for which the risk is modelled by a
Weibull function. This model is very similar to the ‘cured
model’ of de Angelis,21 also used for penetrance estimation in
the genotype-restricted likelihood method.22 Cumulative risks
in the general population used were those published for France
based on data of cancer registries.23
Probabilities for the TN status of a breast tumour were
obtained from the proportion of TN tumours among women
tested for BRCA1/2 data in studies without any selection on
morphological characteristics.15 24 25 Weighting these propor-
tions by the number of women, we obtained an average propor-
tion of TN of 68% among women with BRCA1 mutation and
13% among women with no BRCA1 mutation (including those
with a BRCA2 mutation).14
Mutations in BRCA1 and BRCA2 are rare and involved in
breast cancer in almost equal proportions26 for the two genes.
Neglecting the very infrequent occurrence where individuals are
carriers for both genes, one on BRCA1 and one on BRCA2, we
computed Lðsij; cij; tij; jÞ as the average of risks associated with
the mutations of the two genes weighted by the frequency of
mutation carriers on each gene. For allele frequencies, estimates
as different as 0.00126 and 0.00518 for both genes were found.
We used an intermediate value of 0.001 for each gene, which
was shown to best ﬁt published data27–31 for frequency of car-
riers among affected individuals.14
Evaluation of the performance of the new scoring system
The performance of the new scoring system was evaluated using
simulations of families with breast and/or ovarian cancer. The
main advantage of simulations compared with observed data is
to provide an estimation of absolute sensitivity, that is, the pro-
portion of carrier individuals that fulﬁl the criteria recom-
mended for genetic testing among all affected ones, whereas
observed data only provide an estimation of relative sensitivity
of criteria among the only families that underwent genetic
testing.
The simulation of pedigrees was performed in order to be
representative of families of individuals affected by breast–
ovarian cancer in the French general population. We considered
an affected case, the proband, his/her age (not exceeding
80 years); sex and phenotype (breast, including male breast
cancer, or ovarian cancer) were drawn at random according to
French cancer registries.23 His/her genotype (carrier/non-carrier)
was drawn at random according to the conditional probability
of genotypes, given the disease status obtained from the fre-
quencies of the mutated alleles and the penetrance values men-
tioned above, using Bayes’ theorem. For breast cancer, the TN
status of the tumour was simulated according to its probability
conditional on genotype, as mentioned above.
The pedigree structure was built using demographic data for
France.32 33 In order to take into account the impact of mortal-
ity of mother on sibship structure, the size and structure of sib-
ships were deﬁned as follows:
Women are fertile between 15 and 49 years.
Maternal age at ﬁrst birth was taken as x1=16+X, where X is
a random variable from an exponential distribution with param-
eter λ=0.1. This parameter value was chosen to ﬁt the age at
ﬁrst birth in France according to the birth cohort of the mother.
For i≥1, age of women at the (i+1)th birth was xi+1=
xi+1+X, where X follows an exponential distribution with par-
ameter λ depending on the birth cohort of the mother. The
value of λ was chosen to ﬁt female fertility in France. Note that
we use xi+1 instead of xi to account for the minimum interval
between two births at 1 year.
Fertility could be interrupted either by death or by reaching
the end of reproductive period (age exceeding 49).
The birth ranks of the proband and of his/her parents within
their own sibships were set at random from a uniform
distribution.
The resulting pedigrees include at least three generations,
from the proband’s grandparents to the proband and his/her
ﬁrst cousins, and, if the proband and his/her cousins are old
enough to have children, the pedigrees include a fourth or even
a ﬁfth generation.
The genotype of each member of the family conditional on
the proband’s genotype was simulated following Mendel laws
and using Bayes’ theorem. Their phenotype (disease status and
tumour characteristics) was simulated using the parameters men-
tioned above.
We simulated a total of 10 000 000 families, and we com-
puted for each family its conditional probability P that the
proband is a mutation carrier given the personal and family
history of the disease (H), without knowledge of the simulated
genotype, the Manchester combined score (MCS)15 and the
score obtained by the new system (NSS). The probability P was
computed using the Elston–Stewart algorithm34 and is referred
as PRobability computed using the Elston–STewart algorithm
(PREST). For each of the three methods (PREST, MCS, NSS),
the sensitivity was estimated as the proportion of families with a
score (or a probability P) above a given threshold, among fam-
ilies with a mutation carrier proband. Similarly, the speciﬁcity at
this threshold was estimated as the proportion of families with a
score (or a probability P) below the threshold, among families
with a non-carrier proband. The positive predictive value (PPV)
was estimated as the proportion of carriers among the families
exceeding this threshold. The performance of the three systems
was compared by receiver operating characteristic (ROC) curves,
which represent sensitivity as a function of one minus speciﬁcity
for various threshold values, and also by the curve of PPV as a
function of sensitivity.
Family sample
The scoring system was used on a sample 4563 families
screened for BRCA1 and BRCA2 mutations between 1995 and
2012 in the Institut Curie in Paris. These families have been
tested following the current recommended criteria in
France.3 13 35 Probands had given their informed consent for
BRCA1/2 genetic testing in the setting of a family cancer clinic
and their consent to the use of their anonymised data. Probands
and relatives who gave authorisations to their medical record
access were informed of the computer recording of their family
history. The family database had been declared to the French
national ad hoc authority (CNIL). As the study does not involve
intervention on patients, there was no need to consult an ethics
committee. The point and small-size mutation analyses of the
BRCA1 and BRCA2 genes have been performed from 1995 to
the present by different screening methods, followed by Sanger
sequencing of amplicons showing abnormal screening patterns:
DGGE, DHPLC and EMMA. Regarding large gene rearrange-
ments of both genes, they have been searched using DNA
combing, and later QMPSF and EMMA.
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RESULTS
Simulated families
The values of the new BRCA1/2 mutation scores for the differ-
ent members of a family, according to cancer localisation and
type (TN status for breast cancer), age class at diagnosis and
degree of kinship with the proband are given in table 1 for
affected members and in table 2 for unaffected members. The
score values displayed were obtained by multiplying the original
scores by 2 and by rounding them to integer values in order to
be easily summed by hand. As expected, for cancer at a given
age and localisation, the proband always has the highest score
compared with his/her relatives, and the scores of relatives
decrease with increasing degree of kinship with the proband.
Figure 1 shows the ROC curves for the new scoring system,
for the PREST probability and for the Manchester scoring
system. Figure 2 shows PPV as a function of sensitivity for these
three systems. In ﬁgures 1 and 2, the PREST curves show that
the PREST method performs the best. The NSS curves are con-
sistently closer to the PREST curves than the MCS curves. The
area under the ROC curve is 0.92 for PREST, 0.88 for the
Manchester scoring system and 0.90 for the new system.
To investigate the performance gained in accounting for
unaffected family members and for the degree of kinship of
relatives with the proband, we compared the PPV curves of the
NSS with that of a NSS modiﬁed to ignore either unaffected
family members or kinship coefﬁcients, and ﬁnally both. Each
information type alone slightly improves the prediction and
taken into account all together substantially increases the per-
formance of the system, as shown by the PPV curves (ﬁgure 3).
Table 3 gives the average probability Pr0 obtained by PREST
for various score values of the simulated families, the probability
Pr1 estimated from the proportion of simulated families with a
mutation among those with a score within each score class, and
the probability Pr2 expected from the approximations made for
elaborating the score (see the relationship between P and S in
the ‘Methods’ section). The observed proportion Pr1 is very
close to the Pr0 probability calculated by PREST for all values
of scores. The probability Pr2 is very close to Pr0 and Pr1 for
moderate values of scores but slightly deviates from these prob-
abilities as the score increases.
Table 4 shows the sensitivity, PPV and speciﬁcity of the NSS
for various values of the score threshold recommended for
genetic testing. For comparison, we calculated these parameters
for the Manchester scoring system with a threshold of 16
assumed to correspond to a threshold mutation probability of
10%. The sensitivity was 72%, the PPV was 16% and the speci-
ﬁcity was 88%. We obtained similar PPV and speciﬁcity with the
new system for a score threshold of 5, but the sensitivity was
higher at 77% (see table 4). We recommend this score threshold
of 5 to ensure a good sensitivity.
Table 1 New scores for the proband and affected relatives in the
family (reprinted by permission from Bulletin du Cancer)
Proband
First-degree
relative
Second-degree
relative
Third-degree
relative
Women with breast cancer according to age at onset (years)
<20 11 9 8 7
20–29 7 6 5 4
30–39 5 4 3 2
40–49 4 3 2 1
50–59 4 3 2 1
60–69 2 2 1 1
≥70 0 0 0 0
Women with ovarian cancer according to age at onset (years)
<20 5 4 3 2
20–29 7 6 5 3
30–39 8 7 6 4
40–59 7 6 5 4
≥60 6 5 4 2
Men with breast cancer according to age at onset (years)
<30 23 22 21 19
30–39 16 14 13 11
40–49 11 10 8 7
50–59 10 9 8 6
60–69 8 7 6 4
≥70 7 6 5 3
Triple-negative tumours (if information available)
Yes 3 2 1 1
No -2 -1 0 0
Prostate
cancer
2 1 0 0
Pancreas
cancer
3 2 1 0
Table 2 New scores for unaffected relatives (reprinted by
permission from Bulletin du Cancer)
Age class
(years)
Women Men
First
degree
Second
degree
Third
degree
First
degree
Second
degree
Third
degree
<30 0 0 0 0 0 0
30–49 −0.3 −0.1 0 0 0 0
50–69 −0.7 −0.4 −0.2 0 0 0
≥70 −1 −0.4 −0.2 −0.2 0 0
Figure 1 Receiver operating characteristic curves for the probability of
mutation (PREST), the new scoring system (NSS) and the Manchester
combined score system (MCS).
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The online supplementary appendix gives an example of com-
putation of score in a family. The maternal branch reaches the
score of 9 and would lead to BRCA1/2 screening as it largely
exceeds the score threshold of 5 that we recommend. The
Manchester score would be 16, which is exactly the threshold
recommended for mutation screening.
Families screened at the Institut Curie
Both NSS and PRESTwere computed in the 4563 families. The
scores range from −4 to 31 (to the exception of a single family
with a score of 48, which was discarded from the plots).
Figure 4 shows the frequency polygons of the score values, sep-
arately in families where no mutation was found and in families
where a BRCA1/2 mutation was found. Figure 5 illustrates the
good concordance of the score and PREST values by showing
the score plotted against the transformation of PREST (P) given
at the very end of the ‘Methods’ section.
Table 5 shows the proportion of families with a mutation
according to score value and score threshold. The proportion of
mutations among families according to score value is close to
the results obtained from simulated families, except for low-
score values. On the other hand, the proportion of mutations
according to score threshold is greater than the VPP obtained
from simulated families. This is most likely due to the selection
of families in which the prescription of a genetic test was based
on stringent criteria that favoured very high scores.
Figure 2 Positive predictive value as a function of sensitivity for the
probability of mutation (PREST), the new scoring system (NSS) and the
Manchester combined score system (MCS).
Figure 3 Positive predictive value as a function of sensitivity for the
probability of mutation (PREST), the new scoring system (NSS) and the
Manchester combined score system (MCS).
Table 3 Probability of mutation according to score values in the
new system
Score class Pr0 Pr1 Pr2
[0, 1[ 0.01 0.01 0.00
[1, 2[ 0.01 0.01 0.00
[2, 3[ 0.01 0.01 0.01
[3, 4[ 0.02 0.02 0.01
[4, 5[ 0.03 0.03 0.02
[5, 6[ 0.03 0.04 0.03
[6, 7[ 0.05 0.05 0.05
[7, 8[ 0.08 0.08 0.08
[8, 9[ 0.12 0.13 0.12
[9, 10[ 0.18 0.18 0.18
[10, 11[ 0.25 0.26 0.27
[11, 12[ 0.35 0.37 0.38
[12, 13[ 0.47 0.49 0.50
[13, 14[ 0.57 0.58 0.62
[14, 15[ 0.66 0.67 0.73
[15–16[ 0.74 0.75 0.82
Pr0, probability of mutation obtained by PREST; Pr1, probability estimated from the
proportion of simulated families with a mutation; Pr2, probability expected from the
approximation made for elaborating the score.
Table 4 Performance of the new scoring system according to
threshold for recommending genetic testing
Score threshold Sensitivity Positive predictive value specificity
1 0.93 0.06 0.57
2 0.89 0.08 0.69
3 0.86 0.10 0.76
4 0.82 0.12 0.82
5 0.77 0.15 0.87
6 0.71 0.21 0.92
7 0.65 0.29 0.95
8 0.59 0.38 0.97
9 0.54 0.48 0.98
10 0.49 0.57 0.99
11 0.44 0.66 0.99
12 0.39 0.74 0.99
13 0.34 0.79 0.99
14 0.30 0.84 0.99
15 0.26 0.87 0.99
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DISCUSSION
Our new scoring system is based on the conditional probability
P that a proband is a carrier, given all relevant predictive
information in the family. It is therefore possible to apply it to
other cancer family syndromes such as Lynch syndrome or Li–
Fraumeni syndrome, and even any disease with monogenic sub-
entities due to speciﬁc gene mutations, such as Alzheimer or
Parkinson disease. The only requirement is to know the relative
risks of disease(s) in mutation carriers associated with predictive
factors and the frequency of mutation carriers in the general
population.
In breast–ovarian cancer, the most commonly used system for
identifying BRCA1/2 mutation carriers in France is based on
family conﬁgurations.13 14 This system was shown to perform
rather well, but its performance is difﬁcult to evaluate when
new relevant criteria are added. Our new scoring system was
shown to be an efﬁcient alternative.14 Moreover, as any scoring
system, it may be easily modiﬁed if new predictive factors are
found and relevant information is available. In addition, the
score threshold of 5 that we recommended may be easily modi-
ﬁed if mutation screening cost decreases as expected in the near
future.
An advantage of our method is to rely on theoretical founda-
tions and not on an empirical calculation of scores from a
sample of families selected on familial aggregation of breast or
ovarian cancer cases. Indeed, a method based on observed pro-
portion of mutations in such families should correct for the cri-
teria recommended for genetic testing. This would probably be
not even sufﬁcient since not all families fulﬁlling these criteria
are expected to undergo genetic testing. Such a bias likely
explains the discrepancy in the proportion of mutations in fam-
ilies with low-score values between the families screened at the
Institut Curie and those from the simulated sample.
The improvement of our new scoring system compared with
the Manchester scoring system is mainly the result of incorpor-
ating degrees of kinship of relatives with the proband and
unaffected relatives. This valuable improvement comes at the
cost of a moderately more complicated computation of scores of
families. In the pedigree given in the online supplementary
appendix, the computation of scores may be achieved in a few
seconds using the Manchester scoring system and in about
2 min with the new one. To overcome this complication, we
proposed to use a two-step procedure, with ﬁrst a rough screen-
ing on simple criteria3 by physicians for recommending genetic
counselling followed, if judged relevant, by a ﬁne evaluation by
genetic counsellors using the new scoring system for recom-
mending genetic testing.14
The approximation of the probability P that was made for
elaborating the score system was found to be valid for moderate
values of scores, but slightly differed from the true value as the
score increased. This is only a minor drawback as any system
would recommend genetic testing to the families that have such
high-score values.
Figure 4 Frequency polygon of the score values in families where no
mutation was detected and in families where a BRCA1/2 mutation was
detected.
Figure 5 The score values for the 4563 families plotted against the
transformation of PREST, which is approximated by the score.
Table 5 Proportion of families of the Institut Curie with a
mutation according to score value and score threshold
Score
class
Number
of families
% with
mutation
Score
threshold
Number
of families
% with
mutation
<1 68 1.5 1 4495 16.4
[1, 2[ 81 2.5 2 4414 16.6
[2, 3[ 137 4.4 3 4277 17.0
[3, 4[ 287 5.2 4 3990 17.9
[4, 5[ 580 6.4 5 3410 19.8
[5, 6[ 503 7.8 6 2907 21.9
[6, 7[ 645 8.1 7 2262 25.9
[7, 8[ 543 9.8 8 1719 30.9
[8, 9[ 339 13.0 9 1380 35.4
[9, 10[ 342 17.5 10 1038 41.2
[10, 11[ 266 24.8 11 772 46.9
[11, 12[ 173 24.9 12 599 53.3
[12, 13[ 135 31.1 13 464 59.7
[13, 14[ 94 41.5 14 270 64.3
[14, 15[ 76 61.8 15 294 65.0
≥15 294 65.0 16 233 73.0
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Another limit is that the system relies on uncertain values for
disease risks. However, these risks should be known with
increasing precision in the future and it will be possible to
modify the score values and threshold accordingly. Note that
this limit also holds for methods based on probability computa-
tions. This uncertainty on risks estimates might also affect the
simulations but not the comparison between PREST and the
score systems, given that the same parameters were used.
Finally, the model on which the scoring system is elaborated
does not account for familial factors other than BRCA1 and
BRCA2 that could be another source of familial aggregation.
This is done, for instance, in the BOADICEA model, which
includes, in addition to BRCA1/2 genes, a polygenic compo-
nent9 26 and was shown to perform better for carrier prediction
than other algorithms.36 Such an addition would have consider-
ably complicated the elaboration of the score system and was
not expected to have any impact on sensitivity, but might have
slightly affected PPV and speciﬁcity.
In the present study, we used an original method that gener-
ates families as close as possible to real families in the general
population, particularly by taking into account mortality at
childbearing ages. The interest of using simulations is to provide
estimations of absolute sensitivity, whereas observed data only
provide relative sensitivity. For instance, using simulations per-
mitted to demonstrate that criteria based on positive family
history for BRCA1/2 genetic testing have low sensitivity.37
Estimation of absolute sensitivity is important as recommenda-
tions for genetic testing more and more focus on this parameter,
and not only on PPV.35 In this study, we have shown that the
usual threshold probability of mutation of 10%, corresponding
to a score threshold of about 8 in the new system (table 3),
would lead to a low sensitivity of less than 60% (table 4). In
addition, we must keep in mind that the observed proportion of
families in which a mutation was found may be a poor estima-
tion of PPV as they are most likely selected towards high values
of scores. Indeed, families for which a test is recommended may
not all undergo genetic testing, particularly when only a few
family members are affected. Therefore, families with a score
greater than a given threshold, say 5, have an overrepresentation
of families with higher scores and are not representative of all
families exceeding a score threshold of 5. Therefore, the value
of 15% for PPV found from the simulations is probably a better
estimation of this parameter than the proportion of nearly 20%
found in the sample.
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